Cancer vaccines

BioNTech Announces Full Year 2019 Financial Results and Corporate Update

Tuesday, March 31, 2020 - 11:42am

BioNTech is working to initiate clinical testing for BNT162, a potential first-in-class mRNA vaccine against COVID-19, in late April 2020.

Key Points: 
  • BioNTech is working to initiate clinical testing for BNT162, a potential first-in-class mRNA vaccine against COVID-19, in late April 2020.
  • Details of the agreement regarding financial terms and all activities related to the development, manufacturing and potential commercialization are expected to be finalized shortly.
  • BNT114 Data update from a Phase 1 trial in triple negative breast cancer (TNBC) is now expected in 2H 2020.
  • ET (2:00 p.m. CET) to report its financial results for the full year ended December 31, 2019 and provide a corporate update.

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Thursday, March 26, 2020 - 8:42pm

EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

Key Points: 
  • EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
  • Previously, the process to create an a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.
  • With a personalized cancer vaccine process under 4 weeks, we can safely create a vaccine to treat all stages of aggressive cancer including in the neoadjuvant, adjuvant and metastatic setting.
  • EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

Tuesday, March 24, 2020 - 12:30pm

Dynavax is providing technical expertise and the companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.

Key Points: 
  • Dynavax is providing technical expertise and the companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.
  • CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA).
  • Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
  • Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships.

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

Tuesday, March 24, 2020 - 12:30pm

Clover is advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) in preclinical studies.

Key Points: 
  • Clover is advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) in preclinical studies.
  • Dynavax is providing technical expertise and the companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.
  • CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA).
  • Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships.

MMS Announces One Million Dollar Award for Pharmaceutical Companies Developing a Vaccine for COVID-19

Friday, March 20, 2020 - 1:01pm

MMS Holdings (MMS) an award-winning, data-focused CRO announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus.

Key Points: 
  • MMS Holdings (MMS) an award-winning, data-focused CRO announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus.
  • The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.
  • Our goal is to help eliminate financial roadblocks associated with pursuing approval of a treatment in this area.
  • The company, or companies, chosen to receive this award will be able to draw support in the following areas:

DGAP-News: Abivax 2019 Financial Results and Operations Update

Monday, March 16, 2020 - 7:01pm

The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.

Key Points: 
  • The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.
  • Based on the encouraging results from the Phase 2a induction and maintenance trials, Abivax initiated a Phase 2b study, ABX464-103, in UC and enrolled the first patient in August 2019.
  • Top line results from this trial are expected in Q4 2020.
  • Abivax is currently planning for a start of the enrollment of patients in the second half of 2020.

PDC*line Pharma Announces the Administration of a First Patient With Its Therapeutic Cancer Vaccine Candidate (PDC*lung01) Targeting Non-small Cell Lung Cancer

Tuesday, March 3, 2020 - 7:00am

This patient is under the supervision of Dr. Anne Sibille, principal investigator for the Liege University Hospital (Belgium).

Key Points: 
  • This patient is under the supervision of Dr. Anne Sibille, principal investigator for the Liege University Hospital (Belgium).
  • A total of 62 evaluable HLA-A*02:01 positive NSCLC patients are expected in three clinical centers in Belgium and six in France.
  • We are delighted to have achieved this first important milestone in the clinical development of PDC*line Pharma with our lead cancer vaccine candidate, said Eric Halioua, president and CEO of PDC*line Pharma.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Real-World Study of 6,000+ Medicare Patients with Advanced Prostate Cancer Shows Adding PROVENGE® (sipuleucel-T) to Treatment Regimen Reduced Risk of Death by 45%

Thursday, February 13, 2020 - 7:30pm

Three-year survival rates were significantly higher in men who received PROVENGE in any line of treatment compared to men who never received treatment with PROVENGE (48% vs. 28%; p

Key Points: 
  • Three-year survival rates were significantly higher in men who received PROVENGE in any line of treatment compared to men who never received treatment with PROVENGE (48% vs. 28%; p<0.0001).
  • More than 150 variations of mCRPC treatment sequences were identified in the analysis, underscoring the importance of developing a structured approach to managing mCRPC patients.
  • PROVENGE is the only FDA-approved immunotherapy made from a patients own immune cells for the treatment of prostate cancer.
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Global Neoantigen Cancer Vaccine Market is Projected to Reach $1826.1 Million by End of the Forecast Period, 2030 - ResearchAndMarkets.com

Thursday, January 16, 2020 - 9:44am

Key Questions Answered in this Report:

Key Points: 
  • Key Questions Answered in this Report:
    What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccine market?
  • What are the underlying structures resulting in the emerging trends within the global neoantigen cancer vaccine market?
  • Global Neoantigen Cancer Vaccine Market Forecast, 2023-2030
    The global neoantigen cancer vaccine industry analysis projects the market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030.
  • The neoantigen cancer vaccine market is expected to generate $227.1 million revenue in 2023, owing to the expected launch of first neoantigen vaccine Tedopi in the market.

Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine

Wednesday, January 15, 2020 - 12:30pm

PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.

Key Points: 
  • PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.
  • Developing and validating SNP-7/8a as a personalized cancer vaccine required synthesis of hundreds of unique neoantigen peptides, which were successfully synthesized by Genscript in support of this work.
  • The publication is particularly timely as personalized cancer vaccines are garnering increasing attention among the scientific and medical community as important components to enabling precision immuno-oncology.
  • To support this work, GenScript synthesized hundreds of challenging neoantigen peptides that were selected to have a wide range of properties, including neoantigen peptides with extremes of net charge and hydrophobicity, which was instrumental to enabling Avidea and NIH scientists to validate the generalizability of the SNP-7/8a platform as a personalized cancer vaccine.